Zobrazeno 1 - 10
of 255
pro vyhledávání: '"R B, Diasio"'
Autor:
Yoon, Minha Lea1 (AUTHOR), Chun, Hyelim1 (AUTHOR), Lee, HyunJu1 (AUTHOR), Seo, WooJeong1 (AUTHOR), Lee, Jung Young1 (AUTHOR) stingray@catholic.ac.kr, Yoon, Jung Hwan2 (AUTHOR) 200953093@catholic.ac.kr
Publikováno v:
Cancer Medicine. Dec2024, Vol. 13 Issue 23, p1-11. 11p.
Autor:
R. B Diasio
Publikováno v:
AACR Education book. 2008:461-464
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1bc255890f38f6f535136006709e23f4
https://doi.org/10.1158/aacr.edb-08-8069
https://doi.org/10.1158/aacr.edb-08-8069
Publikováno v:
Cancer research. 53(22)
Dihydropyrimidine dehydrogenase (DPD) is the initial and rate-limiting enzyme in the catabolism of 5-fluorouracil (FUra), one of the most widely used anticancer drugs. Previous studies from our laboratory demonstrated the clinical importance of DPD i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b48725aa8608aada82b9f300030c6883
https://pubmed.ncbi.nlm.nih.gov/8221682
https://pubmed.ncbi.nlm.nih.gov/8221682
Autor:
R. B. Diasio, Zhihong Lu
Publikováno v:
Journal of Clinical Oncology. 12:2239-2242
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bab4b03397bdfaadaedb0ff90456b72d
https://doi.org/10.1200/jco.1994.12.11.2239
https://doi.org/10.1200/jco.1994.12.11.2239
Autor:
Avi I. Einzig, E. L. Schwartz, Peter H. Wiernik, Scott Wadler, Zhihang Lu, R. B. Diasio, Ruiwen Zhang, Joseph A. Sparano
Publikováno v:
Journal of Clinical Oncology. 11:1609-1617
PURPOSE To determine the maximum-tolerable dose (MTD) of fluorouracil (5-FU) administered as a low-dose, prolonged continuous intravenous infusion (PCI) plus interferon-alfa (IFN-alpha) that would permit treatment for at least 28 consecutive days, an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::836397fcdec86894f416d24c786a96e0
https://doi.org/10.1200/jco.1993.11.8.1609
https://doi.org/10.1200/jco.1993.11.8.1609
Autor:
R. Boulieu, A. Lenoir, J. F. Mornex, C. Bohman, J. Balzarini, P. Wigerinck, A. Aerschot, P. Herdewijn, Erik Clercq, S. Brosh, E. Zoref-Shani, O. Sperling, E. Danziger, Y. Sidi, Y. Bromberg, Renate Burgemeister, Elke Rötzer, Wolf Gutensohn, G. P. Connolly, P. J. Harrison, R. B. Diasio, Z. Lu, R. Zhang, U. Gresser, W. Gutensohn, R. Resta, L. F. Thompson, F. Javaux, M. F. Vincent, G. Berghe, I. Kamilli, R. Rauch, D. Hahn, C. W. Keuzenkamp-Jansen, R. A. Abreu, J. P. M. Bökkerink, M. A. H. Heijden, M. Löffler, C. Becker, E. Wegerie, M. Marcussen, K. Overgaard-Hansen, H. Klenow, A. M. Marinaki, E. H. Harley, M. B. McBride, H. A. Simmonds, F. Moro, J. S. Cameron, C. S. Ogg, D. G. Williams, S. Rigden, G. Haycock, M. E. Miranda, J. G. Puig, F. A. Mateos, J. O. Vázquez, V. W. T. Ruiz Haperen, G. Veerman, J. B. Vermorken, G. J. Peters, C. L. Wilt, P. Noordhuis, K. Smid, H. M. Pinedo, C. Salerno, A. Lomonte, O. Giardini, C. Crifo, R. T. Smolenski, M. H. Yacoub, A. M. -L. Seymour, A. P. A. Stegmann, M. W. Honders, R. Willemze, J. E. Landegent, E. H. Stet, G. M. Vogels-Mentink, L. H. J. Lambooy, J. M. F. Trijbels, R. J. Torres, M. G. Tozzi, R. Pesi, M. Turriani, S. Allegrini, M. Camici, P. L. Ipata, A. A. Berg, J. R. Meinsma, H. Lenthe, A. H. Gennip, A. B. P. Kuilenburg, N. G. G. M. Abeling, H. D. Bakker, R. J. Slingerland, F. Bergh, R. L. Sabina
Publikováno v:
Pharmacy World & Science. 15:F7-F14
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::998f79b3fc5c41061e4d3e16542225b7
https://doi.org/10.1007/bf02297670
https://doi.org/10.1007/bf02297670
Autor:
R B, Diasio
Publikováno v:
Oncology (Williston Park, N.Y.). 15(3 Suppl 5)
The treatment of advanced colorectal cancer over the past 4 decades has required the use of intravenous chemotherapy, most typically fluorouracil (5-FU). The possibility of providing an alternative to intravenous delivery while at the same time impro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::47b35a566ec907e026ab957274870a69
https://pubmed.ncbi.nlm.nih.gov/11301835
https://pubmed.ncbi.nlm.nih.gov/11301835
Autor:
R B, Diasio
Publikováno v:
Oncology (Williston Park, N.Y.). 15(1 Suppl 2)
Dihydropyrimidine dehydrogenase (DPD) is the initial rate-limiting enzyme in the catabolism of 5-fluorouracil (5-FU), accounting for catabolism of over 85% of an administered dose of 5-FU. DPD plays an important role in regulating the availability of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1d7be02142efa39ee070ef885c8b5d53
https://pubmed.ncbi.nlm.nih.gov/11219973
https://pubmed.ncbi.nlm.nih.gov/11219973
Autor:
R B, Diasio
Publikováno v:
Oncology (Williston Park, N.Y.). 14(10 Suppl 9)
Over the past decade, increasing data have emphasized both the importance of dihydropyrimidine dehydrogenase (DPD), the initial, rate-limiting enzyme in the catabolism of fluorouracil (5-FU), and its role as a control step in 5-FU metabolism, regulat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b4b25961f537252899ebc2143a803540
https://pubmed.ncbi.nlm.nih.gov/11098485
https://pubmed.ncbi.nlm.nih.gov/11098485
Autor:
D, Salonga, K D, Danenberg, M, Johnson, R, Metzger, S, Groshen, D D, Tsao-Wei, H J, Lenz, C G, Leichman, L, Leichman, R B, Diasio, P V, Danenberg
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 6(4)
We had previously shown that high gene expressions (mRNA levels) of thymidylate synthase (TS; Leichman et al., J. Clin. Oncol., 15: 3223-3229, 1997) and thymidine phosphorylase (TP; Metzger et al., Clin. Cancer Res., 4: 2371-2376, 1998) in pretreatme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c9a1c74d8873c044601f2b9b6a92d2c6
https://pubmed.ncbi.nlm.nih.gov/10778957
https://pubmed.ncbi.nlm.nih.gov/10778957